July 20, 2024

Outrage as NHS rejects life-extending breast cancer drug

Studies had shown that olaparib cut the risk of women with high-risk, early-stage breast cancer who have mutations on the BRCA1 or 2 genes, dying by nearly a third.Studies had shown that olaparib cut the risk of women with high-risk, early-stage breast cancer who have mutations on the BRCA1 or 2 genes, dying by nearly a third.Read MoreHealth News | Mail Online

Leave a Reply

Your email address will not be published. Required fields are marked *